Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone ace...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) Jg. 84; S. 88 - 101 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
01.10.2017
Elsevier Science Ltd |
| Schlagworte: | |
| ISSN: | 0959-8049, 1879-0852, 1879-0852 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT.
Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III–IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis.
We identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53–0.71, p = 0.55 × 10−10), that translates into a 14% absolute improvement in 3-year OS. Despite differences in PFS definitions across trials, we also observed a consistent and highly significant 55% reduction in the risk of clinical/radiological PFS (HR = 0.45, 95% CI = 0.40–0.51, p = 0.66 × 10−36) with the addition of AAP, that translates to a 28% absolute improvement at 3 years. There was no evidence of a difference in the OS benefit by Gleason sum score, performance status or nodal status, but the size of the benefit may vary by age. There were more grade III–IV acute cardiac, vascular and hepatic toxicities with AAP plus ADT but no excess of other toxicities or death.
Adding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom.
•First systematic review of abiraterone acetate plus prednisone/prednisolone (AAP) in hormone-sensitive prostate cancer.•Results based on 2201 men (82% of all eligible), including unreported analyses.•Adding AAP to hormones substantially improves survival and progression-free survival.•Benefits may vary with age, but not nodal or performance status, or Gleason score.•No increased mortality with AAP, but more cardiac, vascular and hepatic toxicity. |
|---|---|
| AbstractList | •
First systematic review of abiraterone acetate plus prednisone/prednisolone (AAP) in hormone-sensitive prostate cancer.
•
Results based on 2201 men (82% of all eligible), including unreported analyses.
•
Adding AAP to hormones substantially improves survival and progression-free survival.
•
Benefits may vary with age, but not nodal or performance status, or Gleason score.
•
No increased mortality with AAP, but more cardiac, vascular and hepatic toxicity. There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III-IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis. We identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53-0.71, p = 0.55 × 10 ), that translates into a 14% absolute improvement in 3-year OS. Despite differences in PFS definitions across trials, we also observed a consistent and highly significant 55% reduction in the risk of clinical/radiological PFS (HR = 0.45, 95% CI = 0.40-0.51, p = 0.66 × 10 ) with the addition of AAP, that translates to a 28% absolute improvement at 3 years. There was no evidence of a difference in the OS benefit by Gleason sum score, performance status or nodal status, but the size of the benefit may vary by age. There were more grade III-IV acute cardiac, vascular and hepatic toxicities with AAP plus ADT but no excess of other toxicities or death. Adding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom. There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III–IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis. We identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53–0.71, p = 0.55 × 10−10), that translates into a 14% absolute improvement in 3-year OS. Despite differences in PFS definitions across trials, we also observed a consistent and highly significant 55% reduction in the risk of clinical/radiological PFS (HR = 0.45, 95% CI = 0.40–0.51, p = 0.66 × 10−36) with the addition of AAP, that translates to a 28% absolute improvement at 3 years. There was no evidence of a difference in the OS benefit by Gleason sum score, performance status or nodal status, but the size of the benefit may vary by age. There were more grade III–IV acute cardiac, vascular and hepatic toxicities with AAP plus ADT but no excess of other toxicities or death. Adding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom. •First systematic review of abiraterone acetate plus prednisone/prednisolone (AAP) in hormone-sensitive prostate cancer.•Results based on 2201 men (82% of all eligible), including unreported analyses.•Adding AAP to hormones substantially improves survival and progression-free survival.•Benefits may vary with age, but not nodal or performance status, or Gleason score.•No increased mortality with AAP, but more cardiac, vascular and hepatic toxicity. Background: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. Methods: Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III-IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis. Findings: We identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53-0.71, p = 0.55 x 10-10), that translates into a 14% absolute improvement in 3-year OS. Despite differences in PFS definitions across trials, we also observed a consistent and highly significant 55% reduction in the risk of clinical/radiological PFS (HR = 0.45, 95% CI = 0.40-0.51, p = 0.66 x 10-36) with the addition of AAP, that translates to a 28% absolute improvement at 3 years. There was no evidence of a difference in the OS benefit by Gleason sum score, performance status or nodal status, but the size of the benefit may vary by age. There were more grade III-IV acute cardiac, vascular and hepatic toxicities with AAP plus ADT but no excess of other toxicities or death. Interpretation: Adding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom. There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT.BACKGROUNDThere is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT.Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III-IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis.METHODSUsing our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge. Thus, we could determine the earliest opportunity for reliable meta-analysis and take account of unavailable trials in interpreting results. We searched multiple sources for trials comparing AAP plus ADT versus ADT in men with mHSPC. We obtained results for the primary outcome of overall survival (OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade III-IV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute toxicity and interaction HRs for the effects on OS by patient subgroups were combined across trials using fixed-effect meta-analysis.We identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53-0.71, p = 0.55 × 10-10), that translates into a 14% absolute improvement in 3-year OS. Despite differences in PFS definitions across trials, we also observed a consistent and highly significant 55% reduction in the risk of clinical/radiological PFS (HR = 0.45, 95% CI = 0.40-0.51, p = 0.66 × 10-36) with the addition of AAP, that translates to a 28% absolute improvement at 3 years. There was no evidence of a difference in the OS benefit by Gleason sum score, performance status or nodal status, but the size of the benefit may vary by age. There were more grade III-IV acute cardiac, vascular and hepatic toxicities with AAP plus ADT but no excess of other toxicities or death.FINDINGSWe identified three eligible trials, one of which was still recruiting (PEACE-1 (NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53-0.71, p = 0.55 × 10-10), that translates into a 14% absolute improvement in 3-year OS. Despite differences in PFS definitions across trials, we also observed a consistent and highly significant 55% reduction in the risk of clinical/radiological PFS (HR = 0.45, 95% CI = 0.40-0.51, p = 0.66 × 10-36) with the addition of AAP, that translates to a 28% absolute improvement at 3 years. There was no evidence of a difference in the OS benefit by Gleason sum score, performance status or nodal status, but the size of the benefit may vary by age. There were more grade III-IV acute cardiac, vascular and hepatic toxicities with AAP plus ADT but no excess of other toxicities or death.Adding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom.INTERPRETATIONAdding AAP to ADT is a clinically effective treatment option for men with mHSPC, offering an alternative to docetaxel for men who are starting treatment for the first time. Future research will need to address which of these two agents or whether their combination is most effective, and for whom. |
| Author | Burdett, Sarah Sydes, Matthew R. Fizazi, Karim Tran, NamPhuong Rydzewska, Larysa H.M. Mason, Malcolm D. Parmar, Mahesh K.B. Clarke, Noel W. Spears, Melissa R. Vale, Claire L. James, Nicholas D. Miladinovic, Branko Sweeney, Christopher J. Tierney, Jayne F. Kheoh, Thian |
| AuthorAffiliation | d Janssen Research & Development, San Diego, CA, USA b Salford Royal NHS Foundation Trust, Salford, UK a MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK f Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK g Queen Elizabeth Hospital, Birmingham, UK c Gustave-Roussy, University of Paris Sud, 114 Rue Edouard Vaillant, Villejuif 94800, France e Cardiff University, School of Medicine, Cardiff, UK h Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA i Janssen Research & Development, Los Angeles, CA, USA |
| AuthorAffiliation_xml | – name: c Gustave-Roussy, University of Paris Sud, 114 Rue Edouard Vaillant, Villejuif 94800, France – name: h Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA – name: e Cardiff University, School of Medicine, Cardiff, UK – name: a MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK – name: b Salford Royal NHS Foundation Trust, Salford, UK – name: d Janssen Research & Development, San Diego, CA, USA – name: g Queen Elizabeth Hospital, Birmingham, UK – name: f Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK – name: i Janssen Research & Development, Los Angeles, CA, USA |
| Author_xml | – sequence: 1 givenname: Larysa H.M. orcidid: 0000-0001-6205-7457 surname: Rydzewska fullname: Rydzewska, Larysa H.M. email: larysa.rydzewska@ucl.ac.uk organization: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK – sequence: 2 givenname: Sarah surname: Burdett fullname: Burdett, Sarah organization: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK – sequence: 3 givenname: Claire L. surname: Vale fullname: Vale, Claire L. organization: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK – sequence: 4 givenname: Noel W. surname: Clarke fullname: Clarke, Noel W. organization: Salford Royal NHS Foundation Trust, Salford, UK – sequence: 5 givenname: Karim surname: Fizazi fullname: Fizazi, Karim organization: Gustave-Roussy, University of Paris Sud, 114 Rue Edouard Vaillant, Villejuif 94800, France – sequence: 6 givenname: Thian surname: Kheoh fullname: Kheoh, Thian organization: Janssen Research & Development, San Diego, CA, USA – sequence: 7 givenname: Malcolm D. surname: Mason fullname: Mason, Malcolm D. organization: Cardiff University, School of Medicine, Cardiff, UK – sequence: 8 givenname: Branko surname: Miladinovic fullname: Miladinovic, Branko organization: Janssen Research & Development, San Diego, CA, USA – sequence: 9 givenname: Nicholas D. surname: James fullname: James, Nicholas D. organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK – sequence: 10 givenname: Mahesh K.B. surname: Parmar fullname: Parmar, Mahesh K.B. organization: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK – sequence: 11 givenname: Melissa R. surname: Spears fullname: Spears, Melissa R. organization: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK – sequence: 12 givenname: Christopher J. surname: Sweeney fullname: Sweeney, Christopher J. organization: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA – sequence: 13 givenname: Matthew R. surname: Sydes fullname: Sydes, Matthew R. organization: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK – sequence: 14 givenname: NamPhuong surname: Tran fullname: Tran, NamPhuong organization: Janssen Research & Development, Los Angeles, CA, USA – sequence: 15 givenname: Jayne F. surname: Tierney fullname: Tierney, Jayne F. organization: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28800492$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUsuO0zAUtdAgplP4ARbIEhs2KY4dJ84IIVWj4SGNxAbWluPctC6JXWy3o3wHP8C3zJfhtMMIuhgkS7Z8zzn3ce4FOrPOAkIvc7LISV6-3Sxgo9WCkrxakHQIe4JmuajqjAhOz9CM1LzOBCnqc3QRwoYQUomCPEPnVAiSvukM_Vy2rbErrBrjVQSfMuDosLKtdyuwuIWtN3sVjbM4rsGr7YiNxUMK3Zq4To-oQkxxjdfOD4meBbDBRLMHvPVuigHWymrwl3h59yuMIcJwIHjYG7idch1kMmVVPwYTnqOnneoDvLi_5-jbh-uvV5-ymy8fP18tbzLNWRGzgleFgk6VkLeq6qqmaIBx1nDORFEVoigpp105YWjX0Vawqm5JyUudxlALxebo_VF3u2sGaDXY6FUvU8OD8qN0ysh_I9as5crtJS8Zyes6Cby5F_Duxw5ClIMJGvpeWXC7IPOaCp7zSvAEfX0C3bidTw0HSQljjFBWlgn16u-KHkr541cC0CNAp9EGD90DJCdyWgq5kdNSyGkpJEknic-ROCFpEw-Wpq5M_zj13ZEKyYfklpdBG0hmtsaDjrJ15nH65Qld98YarfrvMP6P_BuoO-ol |
| CitedBy_id | crossref_primary_10_1016_S0140_6736_18_32486_3 crossref_primary_10_1007_s10741_020_09984_2 crossref_primary_10_1016_j_clgc_2021_08_009 crossref_primary_10_1007_s00520_019_05255_5 crossref_primary_10_1186_s13643_022_02137_6 crossref_primary_10_1097_CM9_0000000000000506 crossref_primary_10_1080_14737140_2021_1856661 crossref_primary_10_1007_s00210_023_02551_0 crossref_primary_10_3389_fonc_2018_00543 crossref_primary_10_1016_S0140_6736_24_00651_2 crossref_primary_10_3390_cells8010043 crossref_primary_10_1038_s41391_018_0055_8 crossref_primary_10_1089_end_2019_0108 crossref_primary_10_1111_bju_14936 crossref_primary_10_1007_s00345_019_02704_y crossref_primary_10_1007_s00345_019_02873_w crossref_primary_10_1186_s13643_025_02752_z crossref_primary_10_1093_cvr_cvz020 crossref_primary_10_3390_cancers15205008 crossref_primary_10_1016_j_clgc_2018_03_006 crossref_primary_10_1093_jjco_hyy129 crossref_primary_10_1093_annonc_mdy071 crossref_primary_10_1016_S0140_6736_20_31952_8 crossref_primary_10_1016_j_ejca_2018_08_010 crossref_primary_10_1016_S0140_6736_22_00367_1 crossref_primary_10_1371_journal_pmed_1003019 crossref_primary_10_1007_s00345_022_04237_3 crossref_primary_10_1016_j_eururo_2019_11_029 crossref_primary_10_1007_s40258_020_00564_x crossref_primary_10_1371_journal_pone_0266771 crossref_primary_10_1016_j_acvd_2019_09_006 crossref_primary_10_1016_j_canlet_2022_215619 crossref_primary_10_2147_RRU_S303215 crossref_primary_10_1007_s40619_019_00530_3 crossref_primary_10_1007_s42452_025_06930_5 crossref_primary_10_3390_cancers15245714 crossref_primary_10_1016_j_euf_2021_04_003 crossref_primary_10_1016_j_clgc_2019_05_001 crossref_primary_10_3389_fonc_2022_877613 crossref_primary_10_3389_fonc_2019_00775 crossref_primary_10_3389_fphar_2017_00788 crossref_primary_10_1111_iju_13512 crossref_primary_10_1097_SP9_0000000000000009 crossref_primary_10_1200_JCO_2018_78_0619 crossref_primary_10_2217_fon_2019_0190 crossref_primary_10_1155_2022_6211059 crossref_primary_10_3390_ijms19051359 crossref_primary_10_1093_jncics_pkaa076 crossref_primary_10_1097_CCO_0000000000000443 crossref_primary_10_1111_bju_15084 crossref_primary_10_3389_fphar_2022_955925 crossref_primary_10_1016_j_euf_2019_01_005 crossref_primary_10_1038_s41391_021_00335_2 crossref_primary_10_1007_s11912_024_01509_6 crossref_primary_10_1007_s15004_024_0731_x crossref_primary_10_1002_cam4_2502 crossref_primary_10_1002_jrsm_1590 crossref_primary_10_1016_j_ejca_2019_04_031 crossref_primary_10_1016_j_ejca_2024_114072 crossref_primary_10_1111_jcmm_14100 crossref_primary_10_1007_s12254_018_0386_0 crossref_primary_10_1016_j_euros_2020_12_006 crossref_primary_10_1200_EDBK_239041 crossref_primary_10_1016_S1470_2045_18_30571_0 crossref_primary_10_1016_j_urolonc_2018_09_005 crossref_primary_10_1007_s00345_019_03060_7 crossref_primary_10_3390_cancers14082017 crossref_primary_10_1016_j_phytol_2019_06_008 crossref_primary_10_1186_s40959_025_00363_0 crossref_primary_10_1016_j_ijrobp_2018_12_001 crossref_primary_10_1007_s40266_019_00677_6 crossref_primary_10_1038_s41572_020_00243_0 crossref_primary_10_1097_PPO_0000000000000418 crossref_primary_10_1016_j_euf_2018_02_004 crossref_primary_10_2147_OTT_S228355 crossref_primary_10_1016_j_eururo_2019_02_003 crossref_primary_10_1007_s13629_024_00419_3 crossref_primary_10_1186_s12885_024_13201_w crossref_primary_10_1016_j_ejps_2022_106254 crossref_primary_10_1016_j_clgc_2024_102096 crossref_primary_10_3389_fonc_2021_769068 crossref_primary_10_1016_j_eururo_2024_04_010 crossref_primary_10_1016_j_tranon_2021_101115 crossref_primary_10_1007_s00761_019_0538_9 crossref_primary_10_1007_s00120_023_02030_7 crossref_primary_10_1080_14737140_2020_1770087 crossref_primary_10_1016_j_euros_2021_08_008 crossref_primary_10_1097_MOU_0000000000000694 crossref_primary_10_1097_SPC_0000000000000359 crossref_primary_10_1016_j_bbamcr_2022_119221 crossref_primary_10_1371_journal_pmed_1003629 crossref_primary_10_1080_14796694_2025_2482360 crossref_primary_10_1007_s00280_020_04133_w crossref_primary_10_1016_j_ejca_2018_01_115 crossref_primary_10_2217_fon_2018_0619 crossref_primary_10_1016_j_ejca_2021_11_026 crossref_primary_10_2147_OTT_S306345 crossref_primary_10_3322_caac_70020 crossref_primary_10_3390_diagnostics11020345 crossref_primary_10_4103_HUAJ_HUAJ_19_20 crossref_primary_10_1016_j_ejphar_2019_172783 crossref_primary_10_1016_j_eururo_2017_09_029 crossref_primary_10_12968_hmed_2022_0334 crossref_primary_10_1097_SPC_0000000000000507 crossref_primary_10_1016_S1470_2045_23_00230_9 crossref_primary_10_1007_s11864_019_0668_8 crossref_primary_10_3390_jcm14082565 crossref_primary_10_1016_S1470_2045_19_30082_8 crossref_primary_10_1002_mc_23565 |
| Cites_doi | 10.1056/NEJMoa1014618 10.1111/iju.13091 10.1136/bmj.j573 10.1001/jama.2015.3656 10.1056/NEJMoa1704174 10.1016/j.jclinepi.2010.11.016 10.1002/sim.1186 10.1056/NEJMoa1702900 10.1016/S0022-4731(85)80024-8 10.1016/S0033-0620(85)80003-7 10.1016/S1569-9056(17)30272-5 10.1677/ERC-10-0187 10.1016/S1470-2045(15)00489-1 10.1158/1078-0432.CCR-10-0567 10.1186/1745-6215-13-168 |
| ContentType | Journal Article |
| Copyright | 2017 The Author(s) Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Science Ltd. Oct 2017 2017 The Author(s) 2017 |
| Copyright_xml | – notice: 2017 The Author(s) – notice: Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Science Ltd. Oct 2017 – notice: 2017 The Author(s) 2017 |
| CorporateAuthor | the STOPCaP Abiraterone Collaborators STOPCaP Abiraterone Collaborators |
| CorporateAuthor_xml | – name: the STOPCaP Abiraterone Collaborators – name: STOPCaP Abiraterone Collaborators |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1016/j.ejca.2017.07.003 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0852 |
| EndPage | 101 |
| ExternalDocumentID | PMC5630199 28800492 10_1016_j_ejca_2017_07_003 S0959804917311103 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_12023/25 – fundername: Medical Research Council grantid: MC_UU_12023/28 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZGI ZXP ~G- ~HD 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW DOVZS LCYCR RIG ZA5 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c534t-4574aefa6e1da7f7b4be353b5538474846252f64aef2ff2d8379d0656c07898a3 |
| ISICitedReferencesCount | 123 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000411333300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0959-8049 1879-0852 |
| IngestDate | Tue Sep 30 16:57:13 EDT 2025 Sun Sep 28 11:11:11 EDT 2025 Tue Oct 07 07:07:20 EDT 2025 Mon Jul 21 05:23:28 EDT 2025 Tue Nov 18 22:46:15 EST 2025 Sat Nov 29 07:06:20 EST 2025 Fri Feb 23 02:30:50 EST 2024 Tue Oct 14 19:36:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Systematic review Androgen deprivation therapy Abiraterone Prostate cancer Metastases Meta-analysis |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c534t-4574aefa6e1da7f7b4be353b5538474846252f64aef2ff2d8379d0656c07898a3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| ORCID | 0000-0001-6205-7457 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC5630199 |
| PMID | 28800492 |
| PQID | 2033302366 |
| PQPubID | 2047469 |
| PageCount | 14 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5630199 proquest_miscellaneous_1928515785 proquest_journals_2033302366 pubmed_primary_28800492 crossref_primary_10_1016_j_ejca_2017_07_003 crossref_citationtrail_10_1016_j_ejca_2017_07_003 elsevier_sciencedirect_doi_10_1016_j_ejca_2017_07_003 elsevier_clinicalkey_doi_10_1016_j_ejca_2017_07_003 |
| PublicationCentury | 2000 |
| PublicationDate | October 2017 2017-10-00 20171001 |
| PublicationDateYYYYMMDD | 2017-10-01 |
| PublicationDate_xml | – month: 10 year: 2017 text: October 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | European journal of cancer (1990) |
| PublicationTitleAlternate | Eur J Cancer |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd Elsevier Science Ltd |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Science Ltd |
| References | Rydzewska, Tierney, Burdett, Vale, Fisher, Mason (bib8) 2017 Attard, Richards, de Bono, Attard, Richards, de Bono (bib3) 2011; 17 James, de Bono, Spears, Clarke, Mason, Dearnaley (bib12) 2017 Lefebvre, Manheimer, Glanville (bib22) 2008 Higgins, Thompson (bib15) 2002; 21 Wong, Wilczynski, Haynes (bib23) 2006; 94 Tierney, Vale, Burdett, Fisher, Rydzewska, Parmar (bib7) 2017; 18 Yusuf, Peto, Lewis, Collins, Sleight (bib13) 1985; 27 Fisher, Copas, Tierney, Parmar (bib16) 2011; 64 Deeks, Higgins, Altman (bib14) 2011 Labrie, Dupont, Belanger, Giguere, Lacoursiere, Emond (bib2) 1985; 23 Fizazi, Tran, Fein, Matsubara, Rodriquez-Antolin, Alekseev (bib11) 2017 Wanling, Meredith, Marc, Susan, Philip, Oliver (bib24) 2017 Shiota, Eto (bib5) 2016; 23 Stewart, Clarke, Rovers, Riley, Simmonds, Stewart (bib9) 2015; 313 Gillessen, Attard, Beer, Beltran, Bossi, Bristow (bib6) 2017:Jun 24 Stenzl, Krivoshik, Baron, Hirmand, Armstrong (bib20) 2016; 27 Sydes, Parmar, Mason, Clarke, Amos, Anderson (bib18) 2012; 13 Smith, Saad, Hussain, Sternberg, Fizazi, Crawford (bib21) 2017; 16 de Bono, Logothetis, Molina, Fizazi, North, Chu (bib4) 2011; 364 Vale, Burdett, Rydzewska, Albiges, Clarke, Fisher (bib10) 2016; 17 Fisher, Carpenter, Morris, Freeman, Tierney (bib17) 2017; 356 Davis, Stockley, Martin, Long, Yip, Coskinas (bib19) 2015; 25 Sharifi, Gulley, Dahut, Sharifi, Gulley, Dahut (bib1) 2010; 17 Labrie (10.1016/j.ejca.2017.07.003_bib2) 1985; 23 Sydes (10.1016/j.ejca.2017.07.003_bib18) 2012; 13 Fisher (10.1016/j.ejca.2017.07.003_bib17) 2017; 356 Sharifi (10.1016/j.ejca.2017.07.003_bib1) 2010; 17 Gillessen (10.1016/j.ejca.2017.07.003_bib6) 2017 Wanling (10.1016/j.ejca.2017.07.003_bib24) 2017 Smith (10.1016/j.ejca.2017.07.003_bib21) 2017; 16 Fizazi (10.1016/j.ejca.2017.07.003_bib11) 2017 Davis (10.1016/j.ejca.2017.07.003_bib19) 2015; 25 Rydzewska (10.1016/j.ejca.2017.07.003_bib8) 2017 Lefebvre (10.1016/j.ejca.2017.07.003_bib22) 2008 Shiota (10.1016/j.ejca.2017.07.003_bib5) 2016; 23 Higgins (10.1016/j.ejca.2017.07.003_bib15) 2002; 21 Fisher (10.1016/j.ejca.2017.07.003_bib16) 2011; 64 Deeks (10.1016/j.ejca.2017.07.003_bib14) 2011 James (10.1016/j.ejca.2017.07.003_bib12) 2017 Stenzl (10.1016/j.ejca.2017.07.003_bib20) 2016; 27 Attard (10.1016/j.ejca.2017.07.003_bib3) 2011; 17 Tierney (10.1016/j.ejca.2017.07.003_bib7) 2017; 18 Vale (10.1016/j.ejca.2017.07.003_bib10) 2016; 17 Wong (10.1016/j.ejca.2017.07.003_bib23) 2006; 94 de Bono (10.1016/j.ejca.2017.07.003_bib4) 2011; 364 Stewart (10.1016/j.ejca.2017.07.003_bib9) 2015; 313 Yusuf (10.1016/j.ejca.2017.07.003_bib13) 1985; 27 29548532 - Eur J Cancer. 2018 May;94:218-219. doi: 10.1016/j.ejca.2018.02.002. 29573942 - Eur J Cancer. 2018 May;94:216-217. doi: 10.1016/j.ejca.2018.01.115. |
| References_xml | – year: 2017 ident: bib12 article-title: Abiraterone for prostate cancer not previously treated with hormone therapy publication-title: N Engl J Med – volume: 13 start-page: 168 year: 2012 ident: bib18 article-title: Flexible trial design in practice – stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial publication-title: Trials – year: 2017 ident: bib11 article-title: Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer publication-title: N Engl J Med – volume: 313 start-page: 1657 year: 2015 end-page: 1665 ident: bib9 article-title: Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement publication-title: JAMA – volume: 94 start-page: 41 year: 2006 end-page: 47 ident: bib23 article-title: Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE publication-title: J Med Libr Assoc – volume: 64 start-page: 949 year: 2011 end-page: 967 ident: bib16 article-title: A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners publication-title: J Clin Epidemiol – volume: 16 start-page: e356 year: 2017 ident: bib21 article-title: A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS) publication-title: Eur Urol Suppl – year: 2017 ident: bib8 article-title: Systematic review and meta-analysis of the effects of abiraterone for hormone-sensitive metastatic prostate cancer – volume: 27 start-page: 335 year: 1985 end-page: 371 ident: bib13 article-title: Beta blockade during and after myocardial infarction: an overview of the randomized trials publication-title: Prog Cardiovasc Dis – volume: 18 start-page: P351 year: 2017 ident: bib7 article-title: Timely and reliable evaluation of the effects of interventions: a framework for adaptive meta-analysis (FAME) publication-title: Trials – year: 2011 ident: bib14 article-title: Chapter 9: analysing data and undertaking meta-analyses publication-title: Cochrane handbook for systematic reviews of interventions version 5.1.0 – volume: 23 start-page: 833 year: 1985 end-page: 841 ident: bib2 article-title: Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival publication-title: J Steroid Biochem – year: 2017:Jun 24 ident: bib6 article-title: Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 publication-title: Eur Urol – volume: 25 year: 2015 ident: bib19 article-title: Randomised phase 3 trial of enzalutamide in first line androgen deprivation for metastatic prostate cancer: ENZAMET (ANZUP 1304) publication-title: Ann Oncol – year: 2017 ident: bib24 article-title: Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer publication-title: J Clin Oncol – volume: 17 start-page: R305 year: 2010 end-page: R315 ident: bib1 article-title: An update on androgen deprivation therapy for prostate cancer publication-title: Endocr Relat Cancer – volume: 21 start-page: 1539 year: 2002 end-page: 1558 ident: bib15 article-title: Quantifying heterogeneity in a meta-analysis publication-title: Stat Med – volume: 23 start-page: 360 year: 2016 end-page: 369 ident: bib5 article-title: Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer publication-title: Int J Urol – volume: 17 start-page: 1649 year: 2011 end-page: 1657 ident: bib3 article-title: New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway publication-title: Clin Cancer Res – volume: 364 start-page: 1995 year: 2011 end-page: 2005 ident: bib4 article-title: Abiraterone and increased survival in metastatic prostate cancer publication-title: N Engl J Med – volume: 27 year: 2016 ident: bib20 article-title: Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial publication-title: Ann Oncol – volume: 356 start-page: j573 year: 2017 ident: bib17 article-title: Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? publication-title: BMJ – start-page: 95 year: 2008 end-page: 150 ident: bib22 article-title: Searching for studies publication-title: Cochrane handbook for systematic reviews of interventions – volume: 17 start-page: 243 year: 2016 end-page: 256 ident: bib10 article-title: Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data publication-title: Lancet Oncol – volume: 364 start-page: 1995 issue: 21 year: 2011 ident: 10.1016/j.ejca.2017.07.003_bib4 article-title: Abiraterone and increased survival in metastatic prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1014618 – volume: 94 start-page: 41 issue: 1 year: 2006 ident: 10.1016/j.ejca.2017.07.003_bib23 article-title: Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE publication-title: J Med Libr Assoc – volume: 18 start-page: P351 issue: Suppl. 1 year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib7 article-title: Timely and reliable evaluation of the effects of interventions: a framework for adaptive meta-analysis (FAME) publication-title: Trials – volume: 23 start-page: 360 issue: 5 year: 2016 ident: 10.1016/j.ejca.2017.07.003_bib5 article-title: Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer publication-title: Int J Urol doi: 10.1111/iju.13091 – volume: 356 start-page: j573 year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib17 article-title: Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? publication-title: BMJ doi: 10.1136/bmj.j573 – year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib8 – volume: 313 start-page: 1657 issue: 16 year: 2015 ident: 10.1016/j.ejca.2017.07.003_bib9 article-title: Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement publication-title: JAMA doi: 10.1001/jama.2015.3656 – year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib11 article-title: Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1704174 – year: 2011 ident: 10.1016/j.ejca.2017.07.003_bib14 article-title: Chapter 9: analysing data and undertaking meta-analyses – volume: 64 start-page: 949 year: 2011 ident: 10.1016/j.ejca.2017.07.003_bib16 article-title: A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.11.016 – volume: 21 start-page: 1539 year: 2002 ident: 10.1016/j.ejca.2017.07.003_bib15 article-title: Quantifying heterogeneity in a meta-analysis publication-title: Stat Med doi: 10.1002/sim.1186 – year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib6 article-title: Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 publication-title: Eur Urol – year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib12 article-title: Abiraterone for prostate cancer not previously treated with hormone therapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1702900 – year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib24 article-title: Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer publication-title: J Clin Oncol – volume: 23 start-page: 833 issue: 5B year: 1985 ident: 10.1016/j.ejca.2017.07.003_bib2 article-title: Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival publication-title: J Steroid Biochem doi: 10.1016/S0022-4731(85)80024-8 – volume: 27 start-page: 335 year: 1985 ident: 10.1016/j.ejca.2017.07.003_bib13 article-title: Beta blockade during and after myocardial infarction: an overview of the randomized trials publication-title: Prog Cardiovasc Dis doi: 10.1016/S0033-0620(85)80003-7 – volume: 16 start-page: e356 issue: 3 year: 2017 ident: 10.1016/j.ejca.2017.07.003_bib21 article-title: A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS) publication-title: Eur Urol Suppl doi: 10.1016/S1569-9056(17)30272-5 – volume: 17 start-page: R305 issue: 4 year: 2010 ident: 10.1016/j.ejca.2017.07.003_bib1 article-title: An update on androgen deprivation therapy for prostate cancer publication-title: Endocr Relat Cancer doi: 10.1677/ERC-10-0187 – volume: 25 issue: Suppl. 4 year: 2015 ident: 10.1016/j.ejca.2017.07.003_bib19 article-title: Randomised phase 3 trial of enzalutamide in first line androgen deprivation for metastatic prostate cancer: ENZAMET (ANZUP 1304) publication-title: Ann Oncol – volume: 27 issue: Suppl. 6 year: 2016 ident: 10.1016/j.ejca.2017.07.003_bib20 article-title: Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial publication-title: Ann Oncol – volume: 17 start-page: 243 issue: 2 year: 2016 ident: 10.1016/j.ejca.2017.07.003_bib10 article-title: Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00489-1 – start-page: 95 year: 2008 ident: 10.1016/j.ejca.2017.07.003_bib22 article-title: Searching for studies – volume: 17 start-page: 1649 issue: 7 year: 2011 ident: 10.1016/j.ejca.2017.07.003_bib3 article-title: New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-0567 – volume: 13 start-page: 168 year: 2012 ident: 10.1016/j.ejca.2017.07.003_bib18 article-title: Flexible trial design in practice – stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial publication-title: Trials doi: 10.1186/1745-6215-13-168 – reference: 29573942 - Eur J Cancer. 2018 May;94:216-217. doi: 10.1016/j.ejca.2018.01.115. – reference: 29548532 - Eur J Cancer. 2018 May;94:218-219. doi: 10.1016/j.ejca.2018.02.002. |
| SSID | ssj0007840 |
| Score | 2.5819912 |
| SecondaryResourceType | review_article |
| Snippet | There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT)... Background: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation... There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT)... • First systematic review of abiraterone acetate plus prednisone/prednisolone (AAP) in hormone-sensitive prostate cancer. • Results based on 2201 men (82% of... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 88 |
| SubjectTerms | Abiraterone Acetic acid Acute toxicity Age Factors Aged Androgen Antagonists - adverse effects Androgen Antagonists - therapeutic use Androgen deprivation therapy Androstenes - adverse effects Androstenes - therapeutic use Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Chi-Square Distribution Clinical trials Clinical Trials as Topic Confidence intervals Deprivation Disease-Free Survival Endocrine therapy Endocrinology Heart diseases Humans Lymphatic Metastasis Male Men Meta-analysis Metastases Metastasis Middle Aged Neoplasm Grading Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - mortality Neoplasms, Hormone-Dependent - pathology Odds Ratio Prednisolone Prednisolone - therapeutic use Prednisone Prednisone - therapeutic use Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Randomization Reduction Risk Factors Subgroups Survival Systematic review Therapy Time Factors Toxicity Treatment Outcome |
| Title | Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0959804917311103 https://dx.doi.org/10.1016/j.ejca.2017.07.003 https://www.ncbi.nlm.nih.gov/pubmed/28800492 https://www.proquest.com/docview/2033302366 https://www.proquest.com/docview/1928515785 https://pubmed.ncbi.nlm.nih.gov/PMC5630199 |
| Volume | 84 |
| WOSCitedRecordID | wos000411333300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-0852 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2aFiFeEHcCpVok-hQ5sr32rs2bFRUVRKoKFcibtfFFTUidKEmrlt_gB_gWvoyZ3fUliVouEi9RFHt9m5OZ2fWZM4S89jPB7SRAkhRPLI_7iRWkLrckS1KYa6dOntmq2YQ4OgoGg_B4q3WrrIW5mIiiCC4vw9l_NTX8BsbG0tm_MHd1UPgBvoPR4RPMDp9_ZPgoVXUqcohv0LP5tFDNMSQKE8AYRX01Hc06uvhKVf6dmXpubCktscoIta8hn4Xh1gJJ7opiNMMaETgqcsWSTHWYjPZ77n5krytCa6IxHsySRvfk2pcAJiHWx1TKURC8GksUH6_Sb-CLv0pdyD2_WsjOYbffrZYSsBRDv-RaWeD-bLjSvYkEx975UA2oSUmK2ful21z7gHhasujMglxZlFP6wZoJVa1w2loRtZtp_x6I0IIscyUABF7Dg-smgyYXcPTJNsKMXvEYd7NxgtpVjlACsEqsYdmA2OxMYcwFHwmX4dYhtyJCHvd7KNAGj7VFdlzhh-CYd6J3B4P3VTohAlXVW92NqfzSJMX1C0Bta3O26xKtzYnUOh-4kWCd3Cf3zMyIRhrRD8hWVjwkd_qG-_GIfNfApg1g0-WUlsCmDWBTA2w6KigAmyKwaQ1sugFsWgKbahC-odHPHzWkqYY0nouuQPox-fT24KR3aJmWIlbiM29peb7wZJZLnjmpFLkYesOM-WzoQ9z3UFaXu76bc9zHzXM3DZgIU8jSeYJtGQLJnpDtAi7wGaEsgdjHmQTzDGF_2OzwgIdsyIUtOXfbxCmff5wYvX1s-zKJS2LlOEbzxWi-2EYaCGuTTjVmptVmbtyblWaNyzpqiPwxoPTGUX41ymTZOnv-7bjdEjmx8Q0L2M4Yth3jvE1eVZshQuFrR1lk0_NFDHNImNahqFabPNVAq26uBGubiBUIVjug-v3qlmJ0qlTwzf_m-T-PfEHu1j5ll2wv5-fZS3I7uViOFvM90hKDYM_8GX8BI5UvRg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adding+abiraterone+to+androgen+deprivation+therapy+in+men+with+metastatic+hormone-sensitive+prostate+cancer%3A+A%C2%A0systematic+review+and+meta-analysis&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Rydzewska%2C+Larysa+H.M.&rft.au=Burdett%2C+Sarah&rft.au=Vale%2C+Claire+L.&rft.au=Clarke%2C+Noel+W.&rft.date=2017-10-01&rft.pub=Elsevier+Science+Ltd&rft.issn=0959-8049&rft.eissn=1879-0852&rft.volume=84&rft.spage=88&rft.epage=101&rft_id=info:doi/10.1016%2Fj.ejca.2017.07.003&rft_id=info%3Apmid%2F28800492&rft.externalDocID=PMC5630199 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon |